By Molecule Class, Semaglutide Leads Today but Cedes Leadership by 2035 Semaglutide holds a commanding 58% share of the obesity GLP-1 market in 2025, underpinned by robust clinical validation from the STEPandSELECT trials, proven cardiovascular benefits, and extensive real-world use
What is the plan if I develop nausea, vomiting, or dehydration
The decline in well-being aligns with additional data showing that GLP-1 users are much more likely to use mental health services, such as psychiatry, counseling, and medication/self-care apps, than similar demographics who dont take GLP-1 drugs
This study specifically aimed to minimize bias through rigorous methodology
Clin Pharmacol Ther 2019
(Similar ingredients are often used in other GLP-1 supplements.) No studies have tested either Lemme or any combination of its ingredients